These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

917 related items for PubMed ID: 16373887

  • 1. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.
    Kennedy L, Herman WH, Strange P, Harris A, GOAL AIC Team.
    Diabetes Care; 2006 Jan; 29(1):1-8. PubMed ID: 16373887
    [Abstract] [Full Text] [Related]

  • 2. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF, Traylor L, Schwartz SL.
    Endocr Pract; 2010 Jan; 16(4):588-99. PubMed ID: 20350924
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
    Misra A, Patel M, Agarwal P, Lodha S, Tandon N, Magdum M, Yajnik C, Ghosh R, Walekar A.
    Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198
    [Abstract] [Full Text] [Related]

  • 4. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group.
    Ann Intern Med; 2005 Oct 18; 143(8):559-69. PubMed ID: 16230722
    [Abstract] [Full Text] [Related]

  • 5. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I, Pérez Manghi F, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB, DUAL V Investigators.
    JAMA; 2016 Mar 01; 315(9):898-907. PubMed ID: 26934259
    [Abstract] [Full Text] [Related]

  • 6. Randomized Trial of Long-Acting Insulin Glargine Titration Web Tool (LTHome) Versus Enhanced Usual Therapy of Glargine Titration (INNOVATE Trial).
    Bajaj HS, Venn K, Ye C, Aronson R.
    Diabetes Technol Ther; 2016 Oct 01; 18(10):610-615. PubMed ID: 27652718
    [Abstract] [Full Text] [Related]

  • 7. Glycated hemoglobin assessment in clinical practice: comparison of the A1cNow point-of-care device with central laboratory testing (GOAL A1C Study).
    Kennedy L, Herman WH, GOAL A1C Study Team.
    Diabetes Technol Ther; 2005 Dec 01; 7(6):907-12. PubMed ID: 16386096
    [Abstract] [Full Text] [Related]

  • 8. Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial.
    Harris SB, Yale JF, Berard L, Stewart J, Abbaszadeh B, Webster-Bogaert S, Gerstein HC.
    Diabetes Care; 2014 Dec 01; 37(3):604-10. PubMed ID: 24170757
    [Abstract] [Full Text] [Related]

  • 9. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á.
    JAMA; 2022 Feb 08; 327(6):534-545. PubMed ID: 35133415
    [Abstract] [Full Text] [Related]

  • 10. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.
    Ann Intern Med; 2008 Oct 21; 149(8):531-9. PubMed ID: 18936501
    [Abstract] [Full Text] [Related]

  • 11. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
    Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O.
    Diabetes Care; 2007 Nov 21; 30(11):2794-9. PubMed ID: 17698615
    [Abstract] [Full Text] [Related]

  • 12. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P.
    Endocr Pract; 2011 Nov 21; 17(1):41-50. PubMed ID: 20713345
    [Abstract] [Full Text] [Related]

  • 13. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.
    Clin Ther; 2007 Nov 21; 29(11):2349-64. PubMed ID: 18158076
    [Abstract] [Full Text] [Related]

  • 14. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure.
    Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P.
    Endocr Pract; 2011 Nov 21; 17(3):395-403. PubMed ID: 21324825
    [Abstract] [Full Text] [Related]

  • 15. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group.
    Diabetes Obes Metab; 2009 Jun 21; 11(6):623-31. PubMed ID: 19515182
    [Abstract] [Full Text] [Related]

  • 16. A comparison between simplified and intensive dose-titration algorithms using AIR inhaled insulin for insulin-naive patients with type 2 diabetes in a randomized noninferiority trial.
    Mathieu C, Cuddihy R, Arakaki RF, Belin RM, Planquois JM, Lyons JN, Heilmann CR.
    Diabetes Technol Ther; 2009 Sep 21; 11 Suppl 2():S53-61. PubMed ID: 19772450
    [Abstract] [Full Text] [Related]

  • 17. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct 21; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

  • 18. Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus.
    Dailey G, Aurand L, Stewart J, Ameer B, Zhou R.
    J Diabetes; 2014 Mar 21; 6(2):176-83. PubMed ID: 23931125
    [Abstract] [Full Text] [Related]

  • 19. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL.
    Clin Ther; 2010 May 21; 32(5):896-908. PubMed ID: 20685497
    [Abstract] [Full Text] [Related]

  • 20. The Effect of Reduced Self-Monitored Blood Glucose Testing After Adoption of Continuous Glucose Monitoring on Hemoglobin A1c and Time in Range.
    Puhr S, Calhoun P, Welsh JB, Walker TC.
    Diabetes Technol Ther; 2018 Aug 21; 20(8):557-560. PubMed ID: 30036082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.